2. シグナル伝達
  3. GPCR/G Protein
  4. P2Y Receptor
  5. P2Y12 Receptor Isoform

P2Y12 Receptor

The P2Y12 receptor is an ADP-activated platelet receptor that plays a central role in platelet activation, thrombus formation, hemostasis, and thrombosis[1][2]. Mechanistically, P2Y12 signaling amplifies platelet activation by supporting αIIbβ3 integrin activation and platelet aggregation through a phosphoinositide 3-kinase-dependent pathway[3]. In thrombin-stimulated platelets, autocrine or added ADP stimulates P2Y12 receptors to enhance and prolong Ca2+ mobilization, with PI3Kβ, rather than PI3Kγ, driving prolonged Ca2+ response, procoagulant activity, and coagulation[4]. In disease-related settings, P2Y12 inhibition supports antithrombotic therapy in coronary artery disease, acute coronary syndrome, myocardial infarction, and percutaneous coronary intervention[5][6]. Compared with related platelet activation pathways, P2Y12 can generate P2Y1-independent inside-out signaling, while PAR-1 and PAR-4 platelet responsiveness may persist despite adequate P2Y12 inhibition[3][7]. For experimental and translational applications, clopidogrel, prasugrel, ticagrelor, cangrelor, and novel reversible antagonists provide tools to study ADP-induced platelet aggregation, receptor specificity, pharmacodynamic variability, and thrombotic disease models[5][8][9].

References:

P2Y12 Receptor 関連製品 (33):

製品番号 製品名 製品効果 純度
  • HY-10064
    Ticagrelor Antagonist 99.95%
    Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
  • HY-15283
    Clopidogrel Inhibitor 99.57%
    Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
  • HY-19638A
    Cangrelor tetrasodium Antagonist 99.96%
    Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist.
  • HY-108660
    PSB-0739 Antagonist 98.0%
    PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y12 receptor antagonist with a Ki values of 24.9 nM. The P2Y12 receptor plays a crucial role in platelet aggregation. Antithrombotic effect.
  • HY-17459
    Clopidogrel hydrogen sulfate Inhibitor 99.88%
    Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor.
  • HY-107752A
    GPR17 agonist 1 Activator
    GPR17 agonist 1 is a selective and potent GPR17 agonist with an EC50 of 35 pM. GPR17 agonist 1 also shows weak activation of P2Y Receptor. GPR17 agonist 1 can be used for the research of neurological disease.
  • HY-109122A
    Selatogrel hydrochloride Antagonist
    Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy.
  • HY-108648
    2-MeS-ADP trisodium Agonist 99.90%
    2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1.
  • HY-134353B
    ADP-β-S trilithium Activator
    ADP-β-S (Adenosine 5'-(β-thiodiphosphate)) trilithium is a non-hydrolyzable ADP analog and a P2Y12 receptor agonist. ADP-β-S trilithium activates the P2Y12 receptor in microglia, thereby triggering downstream inflammatory signaling pathways. ADP-β-S trilithium activates P2Y purinergic receptors in rat pancreatic β cells and enhances glucose-induced insulin secretion. ADP-β-S trilithium can be used in the research of diseases such as inflammation and diabetes.
  • HY-15284
    Prasugrel Inhibitor 99.85%
    Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
  • HY-125989
    2-Methylthio-AMP Antagonist 98.94%
    2-Methylthio-AMP (2-MeSAMP) is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP is an inhibitor of ADP-dependent platelet aggregation.
  • HY-15284A
    Prasugrel hydrochloride Inhibitor 98.49%
    Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
  • HY-15799
    AZD1283 Antagonist 99.33%
    AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders.
  • HY-11021
    Elinogrel Antagonist 98.68%
    Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects.
  • HY-161727
    P2Y14R antagonist 1 Antagonist 98.76%
    P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC50 of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis.
  • HY-15876
    Clopidogrel thiolactone Inhibitor 98.0%
    Clopidogrel thiolactone is an important intermediate in the metabolism of Clopidogrel (HY-15283). Clopidogrel thiolactone has antiplatelet aggregatione effects. Clopidogrel is a P2Y12 receptor inhibitor that exerts antiplatelet effects.
  • HY-10064S
    Ticagrelor-d7 Antagonist
    Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
  • HY-123669
    R-138727 Inhibitor
    R-138727, the major active metabolite of Prasugrel (HY-15284), is a highly potent and selective irreversible antagonist of the P2Y12 receptor, with an IC50 of 2.5 μM. R-138727 covalently binds to the P2Y12 receptor on the platelet surface, blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 can be used to study stroke, cerebral infarction and neurological deficits.
  • HY-15284S1
    Prasugrel-d3 Inhibitor 98.58%
    Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
  • HY-123490
    Regrelor disodium Antagonist 99.89%
    Regrelor disodium (INS 50589) is a platelet P2Y12 receptor antagonist. Regrelor disodium is a well-tolerated, reversible ADP competitive antagonist. Regrelor disodium inhibits cell proliferation. Regrelor disodium can be used in inflammation-related research.